Arcellx, Inc. ( ACLX )

Other

Common Stock

1,479,148

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

11,459

-^{footnote F3}

Apr 28, 2026

Derivative

Stock Option (right to buy)

8,011

-^{footnote F3}

Apr 28, 2026

Derivative

Stock Option (right to buy)

9,174

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR

Apr 28, 2026

Other

Common Stock

1,925

-^{footnote F1}

Apr 28, 2026

Other

Common Stock

2,706

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

11,459

-^{footnote F3}

Apr 28, 2026

Derivative

Stock Option (right to buy)

8,011

-^{footnote F3}

Apr 28, 2026

Derivative

Stock Option (right to buy)

9,174

-^{footnote F3}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR

Apr 28, 2026

Derivative

Stock Option (right to buy)

36,806

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

11,459

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

8,011

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

9,174

-^{footnote F1}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with… Full note on SEC EDGAR

Apr 28, 2026

Derivative

Stock Option (right to buy)

27,077

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

20,513

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

11,459

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

8,011

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

9,174

-^{footnote F1}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with… Full note on SEC EDGAR

Apr 28, 2026

Kristin Myers

Derivative

Stock Option (right to buy)

16,829

-^{footnote F1}

Apr 28, 2026

Kristin Myers

Derivative

Stock Option (right to buy)

1,784

-^{footnote F1}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into Company (the "Merger"), with… Full note on SEC EDGAR

Apr 28, 2026

Other

Common Stock

21,659

-^{footnote F1}

Apr 28, 2026

Derivative

Stock Option (right to buy)

13,626

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

59,405

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

31,794

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

61,538

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

11,459

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

8,011

-^{footnote F2}

Apr 28, 2026

Derivative

Stock Option (right to buy)

9,174

-^{footnote F2}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR

Apr 28, 2026

Andrew H. Galligan

Other

Common Stock

5,000

-^{footnote F1}

Apr 28, 2026

Andrew H. Galligan

Derivative

Stock Option (right to buy)

16,829

-^{footnote F2}

Apr 28, 2026

Andrew H. Galligan

Derivative

Stock Option (right to buy)

1,784

-^{footnote F2}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x)… Full note on SEC EDGAR

Apr 28, 2026

Michelle Gilson - Officer

Other

Common Stock

67,048

-^{footnote F1}

Apr 28, 2026

Michelle Gilson - Officer

Other

Common Stock

5,000

-^{footnote F1}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Stock Option (right to buy)

40,205

-^{footnote F3}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Stock Option (right to buy)

32,500

-^{footnote F3}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Stock Option (right to buy)

70,796

-^{footnote F3}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Stock Option (right to buy)

94,596

-^{footnote F3}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Restricted Stock Unit

20,496

-^{footnote F5}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Restricted Stock Unit

61,590

-^{footnote F5}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Restricted Stock Unit

88,542

-^{footnote F5}

Apr 28, 2026

Michelle Gilson - Officer

Grant or award

Performance-based Restricted Stock Unit

59,028

-^{footnote F5}

Apr 28, 2026

Michelle Gilson - Officer

Derivative

Performance-based Restricted Stock Unit

59,028

-^{footnote F5}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR
Footnote F5 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the… Full note on SEC EDGAR

Apr 28, 2026

Christopher Heery - Officer

Other

Common Stock

23,749

-^{footnote F1}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

10,901

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

43,604

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

132,416

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

40,000

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

76,242

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Stock Option (right to buy)

60,096

-^{footnote F2}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Restricted Stock Unit

13,021

-^{footnote F4}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Restricted Stock Unit

39,194

-^{footnote F4}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Restricted Stock Unit

67,708

-^{footnote F4}

Apr 28, 2026

Christopher Heery - Officer

Grant or award

Performance-based Restricted Stock Unit

45,138

-^{footnote F4}

Apr 28, 2026

Christopher Heery - Officer

Derivative

Performance-based Restricted Stock Unit

45,138

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the… Full note on SEC EDGAR

Apr 28, 2026

Rami Elghandour - Officer

Other

Common Stock

174,887

-^{footnote F1}

Apr 28, 2026

Rami Elghandour - Officer

Other

Common Stock

198,000

-^{footnote F1}

Apr 28, 2026

Rami Elghandour - Officer

Other

Common Stock

218,500

-^{footnote F1}

Apr 28, 2026

Rami Elghandour - Officer

Other

Common Stock

101,164

-^{footnote F1}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

1,068,005

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

837,602

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

120,000

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

245,065

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

255,965

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Stock Option (right to buy)

810,102

-^{footnote F5}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Restricted Stock Unit

55,459

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Restricted Stock Unit

167,973

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Restricted Stock Unit

208,333

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Grant or award

Performance-based Restricted Stock Unit

147,745

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Performance-based Restricted Stock Unit

147,745

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Grant or award

Performance-based Restricted Stock Unit

284,388

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Performance-based Restricted Stock Unit

284,388

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Grant or award

Performance-based Restricted Stock Unit

138,888

-^{footnote F8}

Apr 28, 2026

Rami Elghandour - Officer

Derivative

Performance-based Restricted Stock Unit

138,888

-^{footnote F8}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of… Full note on SEC EDGAR
Footnote F5 (price): Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to… Full note on SEC EDGAR
Footnote F8 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the… Full note on SEC EDGAR

Apr 15, 2026

Michelle Gilson - Officer

Option exercise

Common Stock

36,000

$8.66

$312K

Apr 16, 2026

Michelle Gilson - Officer

Option exercise

Common Stock

2,110

$8.66

$18K

Apr 15, 2026

Michelle Gilson - Officer

Option exercise

Stock Option (right to buy)

36,000

$0.00

Apr 16, 2026

Michelle Gilson - Officer

Option exercise

Stock Option (right to buy)

2,110

$0.00

Mar 17, 2026

Michelle Gilson - Officer

Gift

Common Stock

5,000

$0.00

Mar 4, 2026

Rami Elghandour - Officer

Gift

Common Stock

101,164

$0.00

Jan 2, 2026

Rami Elghandour - Officer

Option exercise

Common Stock

55,459

$0.00

Jan 3, 2026

Rami Elghandour - Officer

Option exercise

Common Stock

53,098

$0.00

Jan 6, 2026

Rami Elghandour - Officer

Option exercise

Common Stock

55,991

$0.00

Feb 27, 2026

Rami Elghandour - Officer

Open-market sale

Common Stock

89,916

$113.92^{footnote F3}

$10.24M

Footnote F3 (price): Represents the weighted average share price of an aggregate total of 89,916 shares sold in the price range of $113.83 to $114.25 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the… Full note on SEC EDGAR

Jan 6, 2026

Michelle Gilson - Officer

Option exercise

Common Stock

20,530

$0.00

Feb 25, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

11,219

$113.82^{footnote F3}

$1.28M

Footnote F3 (price): Represents the weighted average share price of an aggregate total of 11,219 shares sold in the price range of $113.765 to $113.835 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the… Full note on SEC EDGAR

Jan 3, 2026

Michelle Gilson - Officer

Option exercise

Common Stock

15,340

$0.00

Feb 19, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

2,879

$67.73^{footnote F3}

$195K

Feb 19, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

5,405

$68.57^{footnote F4}

$371K

Feb 19, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

100

$69.38

$7K

Footnote F3 (price): Represents the weighted average share price of an aggregate total of 2,879 shares sold in the price range of $67.09 to $68.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer… Full note on SEC EDGAR
Footnote F4 (price): Represents the weighted average share price of an aggregate total of 5,405 shares sold in the price range of $68.17 to $69.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer… Full note on SEC EDGAR

Jan 2, 2026

Michelle Gilson - Officer

Option exercise

Common Stock

20,496

$0.00

Feb 17, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

7,141

$69.21^{footnote F3}

$494K

Feb 17, 2026

Michelle Gilson - Officer

Open-market sale

Common Stock

4,150

$70.01^{footnote F4}

$291K

Footnote F3 (price): Represents the weighted average share price of an aggregate total of 7,141 shares sold in the price range of $68.69 to $69.68 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer… Full note on SEC EDGAR
Footnote F4 (price): Represents the weighted average share price of an aggregate total of 4,150 shares sold in the price range of $69.69 to $70.55 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer… Full note on SEC EDGAR

Feb 11, 2026

Rami Elghandour - Officer

Gift

Common Stock

198,000

$0.00

Jan 20, 2026

Option exercise

Common Stock

6,000

$6.28

$38K

Jan 20, 2026

Open-market sale

Common Stock

6,000

$75.00

$450K

Jan 20, 2026